Mumbai, Nov. 17 -- The inspection, conducted between November 10 and 14, 2025, concluded with zero Form 483 observations, signalling full compliance with regulatory standards.

Nilesh Gupta, MD, Lupin said, "The successful outcome of the U.S. FDA inspection at our Nagpur Unit-1 facility exemplifies our commitment to uphold and maintain the highest standards of quality, compliance, and safety across our facilities. We remain dedicated to improving the lives of our patients globally."

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active ...